Treatment Outcomes in Breast Cancer Patients Aged 65 and Above

IF 0.4 4区 医学 Q4 GERIATRICS & GERONTOLOGY Turkish Journal of Geriatrics-Turk Geriatri Dergisi Pub Date : 2023-01-01 DOI:10.29400/tjgeri.2023.358
Rahşan HABİBOĞLU, İlknur KAYALI, İrem SARICANBAZ
{"title":"Treatment Outcomes in Breast Cancer Patients Aged 65 and Above","authors":"Rahşan HABİBOĞLU, İlknur KAYALI, İrem SARICANBAZ","doi":"10.29400/tjgeri.2023.358","DOIUrl":null,"url":null,"abstract":"Introduction: Despite the increasing number of elderly patients with breast cancer, optimal treatment options remain limited. This study aims to evaluate the clinical characteristics, treatment approaches, and survival outcomes of the patient group aged 65 and above who were treated for breast cancer at our clinic. Materials and Methods: The data of breast cancer patients aged 65 and above who received treatment and follow-up at our clinic between 2012 and 2018 were retrospectively analyzed. Overall survival and disease-free survival analyses were performed using Kaplan-Meier analysis, and comparisons were conducted using the log-rank test. Results: A total of 108 elderly female patients with breast cancer were included in the study. The median follow-up duration was 79.75 months (6.64 years), with a maximum follow-up of 133.49 months (11.12 years). At the end of this period, 88 patients (81.48%) were still alive. The 3-year overall survival rate was 93.5%, and the 5-year overall survival rate was 86.1%. The 3-year disease-free survival rate was 91.6%, and the 5-year disease-free survival rate was 88.7%. Conclusion: When making treatment decisions for elderly breast cancer patients, factors such as performance status, comorbidities, toxicity, and post-treatment quality of life should be carefully considered alongside age. Treatment decisions should be based on comprehensive evaluations taking these factors into account. Keywords: Breast Neoplasms; Treatment Outcome; Aged; Mastectomy; Drug Therapy; Radiotherapy.","PeriodicalId":51196,"journal":{"name":"Turkish Journal of Geriatrics-Turk Geriatri Dergisi","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Geriatrics-Turk Geriatri Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29400/tjgeri.2023.358","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Despite the increasing number of elderly patients with breast cancer, optimal treatment options remain limited. This study aims to evaluate the clinical characteristics, treatment approaches, and survival outcomes of the patient group aged 65 and above who were treated for breast cancer at our clinic. Materials and Methods: The data of breast cancer patients aged 65 and above who received treatment and follow-up at our clinic between 2012 and 2018 were retrospectively analyzed. Overall survival and disease-free survival analyses were performed using Kaplan-Meier analysis, and comparisons were conducted using the log-rank test. Results: A total of 108 elderly female patients with breast cancer were included in the study. The median follow-up duration was 79.75 months (6.64 years), with a maximum follow-up of 133.49 months (11.12 years). At the end of this period, 88 patients (81.48%) were still alive. The 3-year overall survival rate was 93.5%, and the 5-year overall survival rate was 86.1%. The 3-year disease-free survival rate was 91.6%, and the 5-year disease-free survival rate was 88.7%. Conclusion: When making treatment decisions for elderly breast cancer patients, factors such as performance status, comorbidities, toxicity, and post-treatment quality of life should be carefully considered alongside age. Treatment decisions should be based on comprehensive evaluations taking these factors into account. Keywords: Breast Neoplasms; Treatment Outcome; Aged; Mastectomy; Drug Therapy; Radiotherapy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
65岁及以上乳腺癌患者的治疗效果
导读:尽管老年乳腺癌患者数量不断增加,但最佳治疗方案仍然有限。本研究旨在评价65岁及以上患者在我院接受乳腺癌治疗的临床特点、治疗方法及生存结局。材料与方法:回顾性分析我院2012年至2018年65岁及以上接受治疗及随访的乳腺癌患者资料。采用Kaplan-Meier分析进行总生存期和无病生存期分析,采用log-rank检验进行比较。结果:共纳入108例老年女性乳腺癌患者。中位随访时间79.75个月(6.64年),最长随访时间133.49个月(11.12年)。随访结束时,88例患者(81.48%)仍然存活。3年总生存率为93.5%,5年总生存率为86.1%。3年无病生存率为91.6%,5年无病生存率为88.7%。结论:在对老年乳腺癌患者进行治疗决策时,除考虑年龄外,还应认真考虑运动状态、合并症、毒性、治疗后生活质量等因素。治疗决定应基于综合评估,考虑到这些因素。关键词:乳腺肿瘤;治疗效果;岁的;乳房切除术;药物治疗;放射治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
46
审稿时长
6-12 weeks
期刊介绍: Turkish Journal of Geriatrics is a peer-reviewed journal. Official language of the journal is English. Turkish Journal of Geriatrics invites submission of Original Articles based on clinical and laboratory studies. Review Articles are published only after the invitation from the Editorial Board.
期刊最新文献
Relationship Between Different Nutritional Scores in Elderly Patients with Acute Decompensated Heart Failure in the Coronary Intensive Care Unit Comparison of breast cancer patients over the age of 70 and under the age of 35 COVID-19 Vaccine Refusal and Associated Factors: A Population-Based Descriptive Study A Single-Center, Cross-Sectional Prevalence Study of Cervical Diffuse Idiopathic Skeletal Hyperostosis Factors affecting drug interactions and their clinical importance in geriatric outpatients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1